DARIC-NK Program

About Coeptis Therapeutics

Coeptis Therapeutics is advancing a differentiated pipeline of engineered cell therapies focused on overcoming the major challenges of antigen escape and treatment accessibility in oncology. Its core technologies include SNAP-CAR, a multi-antigen targeting CAR-T platform, and DARIC, a universal, multi-donor NK cell platform. The company is progressing its lead asset, COEP-001 (SNAP-CAR CD19), into clinical development for B-cell malignancies, positioning itself in the competitive but high-potential cell therapy market. As a pre-revenue, publicly traded biotech, its strategy hinges on validating its platforms through clinical proof-of-concept to attract partnership and development capital.

Therapeutic Areas

Other Hematologic Malignancies Drugs